These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 7438690)

  • 1. Kinetic and clinical observations in cyanotic children on propranolol therapy.
    Riopel DA; Walle T
    Clin Pharmacol Ther; 1980 Dec; 28(6):743-50. PubMed ID: 7438690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Massive propranolol metabolite retention during maintenance hemodialysis.
    Stone WJ; Walle T
    Clin Pharmacol Ther; 1980 Oct; 28(4):449-55. PubMed ID: 7408404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 4-Hydroxypropranolol and its glucuronide after single and long-term doses of propranolol.
    Walle T; Conradi EC; Walle UK; Fagan TC; Gaffney TE
    Clin Pharmacol Ther; 1980 Jan; 27(1):22-31. PubMed ID: 7351114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of hypersensitivity to adrenergic stimulation after abrupt withdrawal of propranolol and nadolol: influence of half-life differences.
    Krukemyer JJ; Boudoulas H; Binkley PF; Lima JJ
    Am Heart J; 1990 Sep; 120(3):572-9. PubMed ID: 2389694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of dose and uremia on plasma and urine profiles of propranolol metabolites.
    Schneck DW; Pritchard JF; Gibson TP; Vary JE; Hayes AH
    Clin Pharmacol Ther; 1980 Jun; 27(6):744-55. PubMed ID: 7379441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma concentrations of propranolol and 4-hydroxypropranolol during chronic oral propranolol therapy.
    Wong L; Nation RL; Chiou WL; Mehta PK
    Br J Clin Pharmacol; 1979 Aug; 8(2):163-7. PubMed ID: 486291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacology of 4-hydroxypropranolol, a metabolite of propranolol.
    Fitzgerald JD; O'Donnell SR
    Br J Pharmacol; 1971 Sep; 43(1):222-35. PubMed ID: 4400184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Food-induced increase in propranolol bioavailability--relationship to protein and effects on metabolites.
    Walle T; Fagan TC; Walle UK; Oexmann MJ; Conradi EC; Gaffney TE
    Clin Pharmacol Ther; 1981 Dec; 30(6):790-5. PubMed ID: 7307427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rectal and intravenous propranolol infusion to steady state: kinetics and beta-receptor blockade.
    de Leede LG; Hug CC; de Lange S; de Boer AG; Breimer DD
    Clin Pharmacol Ther; 1984 Feb; 35(2):148-55. PubMed ID: 6319066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathophysiologic and pharmacokinetic determinants of the antihypertensive response to propranolol.
    Esler M; Zweifler A; Randall O; DeQuattro V
    Clin Pharmacol Ther; 1977 Sep; 22(3):299-308. PubMed ID: 330078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Timolol and propranolol: bioavailability, plasma concentrations, and beta blockade.
    Wilson TW; Firor WB; Johnson GE; Holmes GI; Tsianco MC; Huber PB; Davies RO
    Clin Pharmacol Ther; 1982 Dec; 32(6):676-85. PubMed ID: 7140133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myocardial sensitivity to isoproterenol following abrupt propranolol withdrawal in conscious dogs.
    Webb JG; Newman WH; Walle T; Daniell HB
    J Cardiovasc Pharmacol; 1981; 3(3):622-35. PubMed ID: 6168842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Propranolol glucuronide cumulation during long-term propranolol therapy: a proposed storage mechanism for propranolol.
    Walle T; Conradi EC; Walle UK; Fagan TC; Gaffney TE
    Clin Pharmacol Ther; 1979 Dec; 26(6):686-95. PubMed ID: 498710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic propranolol administration during pregnancy. Maternal pharmacokinetics.
    Smith MT; Livingstone I; Eadie MJ; Hooper WD; Triggs EJ
    Eur J Clin Pharmacol; 1983; 25(4):481-90. PubMed ID: 6653642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Studies of the absorption and removal of propranolol in hypertensive patients during therapy.
    Chidsey CA; Morselli P; Bianchetti G; Morganti A; Leonetti G; Zanchetti A
    Circulation; 1975 Aug; 52(2):313-8. PubMed ID: 1149212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Propranolol decreases cardiac work in a dose-dependent manner in severely burned children.
    Williams FN; Herndon DN; Kulp GA; Jeschke MG
    Surgery; 2011 Feb; 149(2):231-9. PubMed ID: 20598332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of propranolol: a review.
    Shand DG
    Postgrad Med J; 1976; 52 Suppl 4():22-25. PubMed ID: 787953
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma levels and effects of metoprolol on blood pressure and heart rate in hypertensive patients after an acute dose and between two doses during long-term treatment.
    Bengtsson C; Johnsson G; Regårdh CG
    Clin Pharmacol Ther; 1975 Apr; 17(4):400-8. PubMed ID: 235398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Etintidine-propranolol interaction study in humans.
    Huang SM; Weintraub HS; Marriott TB; Marinan B; Abels R
    J Pharmacokinet Biopharm; 1987 Dec; 15(6):557-68. PubMed ID: 2897462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A radioreceptor assay for propranolol and 4-hydroxypropranolol.
    Rochester CL; Gammon DE; Shane E; Bilezikian JP
    Clin Pharmacol Ther; 1980 Jul; 28(1):32-9. PubMed ID: 6248289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.